drugset / Trial / NCT01070485
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-03
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |